Gadolinium-enhanced aneurysm wall imaging of unruptured intracranial aneurysms
Completed
- Conditions
- Unruptured intracranial aneurysm - protuberance of a blood vessel10002363
- Registration Number
- NL-OMON41834
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
18 years or older.
Patient is diagnosed with one or more unruptured intracranial aneurysms confirmed on digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA).
Informed consent signed by subject.
Exclusion Criteria
Medical history of sever renal insufficiency: GFR<30ml/min/1.73m; nephrogenic systemic fibrosis / nephrogenic fibrosing nephropathy (NSF/NFD).
Gadolinium contrast allergy.
Pregnancy.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The presence (present/absent) of gadolinium-enhancement of the aneurysm wall on<br /><br>3 Tesla MR-angiography (MRA).<br /><br><br /><br>If evaluation of the first 15 patients results in the possibility of a<br /><br>semi-quantitative outcome endpoint for contrast enhancement<br /><br>(none/mild/severe/complete), we will discuss the use of this endpoint with the<br /><br>entire study group.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Determinants of gadolinium-enhancement:<br /><br>a. The use of anti-inflammatory drugs (including acetylsalicylic acid);<br /><br>b. Hypertension;<br /><br>c. The size of the aneurysm;<br /><br>d. The relation with smoking.</p><br>